Alignment Healthcare (ALHC) Stock Forecast & Price Target

Alignment Healthcare is supported by a compelling Medicare Advantage growth engine that is taking share as national carriers retrench, with membership reaching approximately 294k in 2Q26, revenue up 32% to $1.3B, and adjusted EBITDA up 48% to $68mm. Its positive outlook is reinforced by the AVA technology platform and Care Anywhere model, which target high-cost members more precisely and have helped drive a 40 bps Y/Y improvement in adjusted MBR to 86.3% despite rapid enrollment growth. The long-term case is further strengthened by management’s estimate of about $880mm in embedded gross profit potential in the existing membership base, expanding operating leverage, $702mm of cash and investments, and a manageable $324mm debt load due in November 2029.

Alignment Healthcare is viewed negatively because 3Q26 showed only a slight EBITDA miss while 2026 EBITDA guidance was cut sharply from a midpoint of $154m to “no less than” $100m, signaling a materially weaker earnings base. The outlook is further pressured by persistent institutional acute care costs, incremental second-half investments of about $10mm–$11mm, and limited visibility on MLR improvement, which could leave 2027 profitability uncertain. Most importantly, the loss of H3815’s 4.0-star rating for bonus year 2028 puts roughly 75% of membership below the quality bonus threshold, creating material uncertainty around benefit flexibility, competitive positioning, and future plan economics.